Many Amicus Therapeutics, Inc.(FOLD) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Company shares were Upgraded by Robert W. Baird on Jan 24, 2017 to Outperform, Raises Price Target to $ 10 from a previous price target of $7 .
Company has reported several Insider transactions to the SEC, on Feb 9, 2017, Hung Do (Chief Science Officer) sold 25,000 shares at 6.00 per share price.On Nov 10, 2016, Daphne Quimi (SVP, Finance) sold 8,546 shares at 8.00 per share price.On Sep 22, 2016, William D Iii Baird (Chief Financial Officer) sold 20,500 shares at 8.00 per share price.
Amicus Therapeutics Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.33 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $-0.31. The company had revenue of $2.10 million for the quarter, compared to analysts expectations of $2.16 million.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1 by 6 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares are expected to touch $12.33 in the short term. This short term price target has been shared by 6 analysts. However, the standard deviation of short term price estimate has been valued at 3.08. The target price could hit $15 on the higher end and $8 on the lower end.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) rose 2.15% or 0.13 points on Tuesday and made its way into the gainers of the day. After trading began at $6.05 the stock was seen hitting $6.22 as a peak level and $6.01 as the lowest level. The stock ended up at $6.18. The daily volume was measured at 1,541,997 shares. The 52-week high of the share price is $9.8306 and the 52-week low is $4.41. The company has a market cap of $882 million.
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.